Bear Stearns Healthcare Conference In Brief
This article was originally published in The Tan Sheet
Executive Summary
Ross growth opportunities: Ensure Glucerna nutritional food brand for blood sugar control in people with type 2 diabetes and "other disease-specific nutritionals is an area that offers strong future growth potential for Ross," Tom Freyman, Abbott Labs Senior VP & CFO tells analysts at Bear Stearns Healthcare Conference in New York City on Sept. 8-9. Ross' overall business remains attractive to parent firm Abbott due to its strong cash flow, exceptional return on invested capital, exec notes, adding "our goal now is to improve sales growth" of the division. Ross' ProSure nutritional formula for patients with cancer-induced weight loss has been "well-received in institutions, and the success of our aggressive awareness campaign has resulted in the ability to accelerate the retail strategy," Freyman adds. Abbott recently announced plans to increase its focus, investment on higher margin medical and pharmaceutical products in its portfolio, spin off its hospital products division into a separate publicly traded company (1"The Tan Sheet" Aug. 25, 2003, p. 7)...
You may also be interested in...
Abbott To Spin Off Hospital Products Unit To Focus On High-Margin Products
Abbott Laboratories' Ross consumer health care division will be unaffected by the company's spin-off of its Hospital Products unit, announced Aug. 22
Perrigo New Products Include Branded Weight-Loss Supplement, Kid’s Multi
Perrigo introduced two branded products developed in-house at the National Association of Chain Drug Stores Marketplace June 8-10: Dr. Steven Rosenblatt's Ephedra Free Starch Blocker with Phase 2 Starch Neutralizer and Sesame Street Complete Children's Multivitamin Multimineral Supplement
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC